Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

Jacob D. Soumerai,Andy Ni,Anna Alperovich,Connie Lee Batlevi,Kurt S. Bantilan,Thais Fischer,Amanda R. Copeland,Katy Smith,Zhitao Ying,Anas Younes,Andrew D. Zelenetz

Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

2020

Jacob D. Soumerai
Andy Ni
Anna Alperovich
Connie Lee Batlevi
Kurt S. Bantilan
Thais Fischer
Amanda R. Copeland
Katy Smith
Zhitao Ying
Anas Younes
Andrew D. Zelenetz

It is difficult to demonstrate an overall survival (OS) benefit in trials of immediate therapy vs observation in follicular lymphoma (FL). Time to 2nd treatment (TT2T) may be a preferred endpoint. ...

Keywords:

in patient
Internal medicine
Follicular lymphoma
Medicine
advanced stage
Immunology
overall survival
Oncology
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations